The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy

The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy

Objectives

The investigators aim to determine optimal timing of primaquine administration in addition to ACT by comparing administration on day 0 with administration on day 2

PI Institution(s)

Principal Investigator (PI)

Partner(s)

Abstract

The investigators' Hypothesis is that "The correct timing of gametocytocidal drug in combination with an effective Artemisinin Combination Therapy can limit the infectiousness of malaria-infected individuals to less than one week after initiation of treatment" The investigators' primary end points are gametocyte prevalence and density by microscopy and Quantitative Nucleic Acid Based Amplification (QT-NASBA) on day 14, which will be compared between the two primaquine treatment arms.

https://clinicaltrials.gov/ct2/show/NCT01906788

Key facts

  • Dates
    May 2013 to Oct 2013

MESA tags

  • Methodology
    Operational research, Product development & clinical research
    Theme(s)
    Drug-based strategies, Tools for elimination